ANAPTYSBIO reports 100 First Tracks shares
ANAPTYSBIO, INC, identified as a ten percent owner of First Tracks Biotherapeutics, Inc., filed an initial ownership report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ANAPTYSBIO, INC, identified as a ten percent owner of First Tracks Biotherapeutics, Inc., filed an initial ownership report. In connection with the spin-off of First Tracks under a Separation and Distribution Agreement dated April 1, 2026, ANAPTYSBIO owns all 100 outstanding shares of First Tracks common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. In connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") by the Reporting Person, as defined in the Separation and Distribution Agreement, dated April 1, 2026, between the Reporting Person and First Tracks, a wholly owned subsidiary of the Reporting Person, the Reporting Person on April 1, 2026 owns all 100 outstanding shares of common stock of First Tracks.
Key Figures
Key Terms
spin-off financial
Separation and Distribution Agreement financial
ten percent owner regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership in First Tracks Biotherapeutics does ANAPTYSBIO, INC report?
What transaction is associated with ANAPTYSBIO’s First Tracks holdings on April 1, 2026?
Why does ANAPTYSBIO, INC qualify as a ten percent owner in this filing?
What agreement governs the spin-off of First Tracks Biotherapeutics from ANAPTYSBIO?
AI-generated analysis. How Rhea-AI works. Not financial advice.